Shares of TG Therapeutics, Inc. (NASDAQ:TGTX – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the six brokerages that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $31.83.
Several research analysts recently issued reports on the company. B. Riley upped their target price on TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. HC Wainwright restated a “buy” rating and set a $49.00 price objective on shares of TG Therapeutics in a report on Tuesday, August 6th. LADENBURG THALM/SH SH lifted their target price on shares of TG Therapeutics from $39.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, May 2nd. Finally, The Goldman Sachs Group upped their price target on shares of TG Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a research note on Wednesday, August 7th.
View Our Latest Research Report on TG Therapeutics
Hedge Funds Weigh In On TG Therapeutics
TG Therapeutics Stock Performance
Shares of NASDAQ:TGTX opened at $25.19 on Friday. The firm has a 50 day moving average of $19.43 and a 200 day moving average of $16.89. The company has a quick ratio of 2.84, a current ratio of 3.62 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $3.89 billion, a price-to-earnings ratio of 109.52 and a beta of 2.23. TG Therapeutics has a 52 week low of $6.46 and a 52 week high of $25.29.
TG Therapeutics (NASDAQ:TGTX – Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.08. The business had revenue of $73.47 million for the quarter, compared to the consensus estimate of $65.92 million. TG Therapeutics had a return on equity of 31.34% and a net margin of 14.24%. The business’s revenue was up 357.0% compared to the same quarter last year. During the same period last year, the business posted ($0.34) EPS. On average, sell-side analysts predict that TG Therapeutics will post -0.01 earnings per share for the current fiscal year.
TG Therapeutics Company Profile
TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
Featured Stories
- Five stocks we like better than TG Therapeutics
- What does consumer price index measure?
- Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- 2 Option Strategies to Maximize Profits in a Bear Market
- 3 Warren Buffett Stocks to Buy Now
- Lululemon Stock Gears Up for a Massive Comeback Rally
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.